BOSTON, Nov. 7, 2016 /PRNewswire/ -- Stealth BioTherapeutics ( Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that the abstract, "Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) during Stent Revascularization in Patients with Atherosclerotic Renal Artery Stenosis" has been accepted as a late-breaking clinical trial poster at the American Society of Nephrology (ASN) Kidney Week 2016 taking place in Chicago, November 15-20, 2016.
"The EVOLVE trial underscores our commitment to our cardiorenal program," said Stealth's Chief Executive Officer Reenie McCarthy. "We are pleased to present the details of these results both in the context of our three ongoing Phase 2 heart failure studies, as well as to inform our approach to other diseases of aging in which mitochondrial dysfunction is a contributing factor." EVOLVE was a double-blind, placebo-controlled study that evaluated 14 patients ages 40 to 80 with chronic kidney disease (CKD) at risk of acute kidney injury (AKI). The primary endpoint was change in kidney function, and the secondary endpoint was a change in renal blood flow and cortical perfusion. Additional information on the late-breaking clinical trial poster presentation: "Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) during Stent Revascularization in Patients with Atherosclerotic Renal Artery Stenosis"Presented by: Ahmed Saad, M.D., Sandra Herrmann, M.D., Lilach O. Lerman, M.D., Ph.D., and principal investigator, Stephen C. Textor, M.D.Date & Time of Poster Presentation: Friday, November 18 from 10:00 A.M. to 12:00 P.M. CT Location: Exhibit Halls F1/F2Poster Number: FR-PO1124